Table 2.
Individual participant data for the spastic CP single injection group (SCP1) and multiple injection group (SCP3)
| Sex | Class | GMFCS | AFO | Dose | Muscle volume (ml) | Fascicle length (mm) | PCSA (cm2) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | 12 months | Baseline | 12 months | Baseline | 12 months | ||||||
| SCP1 | |||||||||||
| 1 | F | H (R) | I | NO | 96 | 34.1 | 40.4 | 54.0 | 54.0 | 6.5 | 7.4 |
| 2 | M | H (L) | I | SLD (L) | 83 | 16.5 | 18.2 | 22.3 | 29.0 | 7.4 | 7.5 |
| 3 | M | D | I | SLD (B) | 78 | 13.3 | 15.7 | 37.3 | 42.0 | 3.6 | 3.7 |
| 4 | F | D | II | SLD (B) | 79 | 9.0 | 12.9 | 33.0 | 37.3 | 2.7 | 3.4 |
| 5 | M | D | II | HNGD (B) | 96 | 47.6 | 53.3 | 58.6 | 59.3 | 8.1 | 8.8 |
| 6 | M | D | I | SLD (B) | 125 | 34.8 | 38.9 | 57.4 | 58.2 | 6.0 | 6.6 |
| Median | 89.4 | 25.3 | 28.5a | 45.7 | 48.0a | 6.2 | 7.0a | ||||
| MAD | 8.7 | 10.8 | 12.3 | 12.2 | 10.4 | 1.6 | 1.2 | ||||
| r | 0.61 | 0.58 | 0.61 | ||||||||
| SCP3 | |||||||||||
| 1 | M | D | I | HNGD (B) | 297 | 27.5 | 30.3 | 42.8 | 44.8 | 6.4 | 6.6 |
| 2 | M | H (L) | I | NO | 292 | 19.7 | 23.1 | 45.3 | 46.0 | 4.5 | 4.9 |
| 3 | M | D | I | SLD (B) | 346 | 26.6 | 29.9 | 57.0 | 58.5 | 4.7 | 5.0 |
| 4 | F | D | II | SLD | 205 | 11.1 | 15.1 | 51.2 | 52.4 | 2.1 | 2.8 |
| 5 | F | H (R) | I | NO | 320 | 27.4 | 33.1 | 43.1 | 44.8 | 6.4 | 7.2 |
| 6 | M | H (R) | I | NO | 331 | 38.2 | 44.9 | 42.7 | 44.3 | 9.0 | 9.8 |
| 7 | M | D | II | SLD (B) | 329 | 28.7 | 34.1 | 35.1 | 41.8 | 8.1 | 8.2 |
| Median | 320.4 | 27.4 | 30.3a | 43.1 | 44.8a | 6.4 | 6.6a | ||||
| MAD | 23.4 | 1.3 | 3.8 | 2.2 | 1.2 | 1.7 | 1.7 | ||||
| r | 0.61 | 0.63 | 0.61 | ||||||||
There were no significant differences in the baseline or follow-up measures for MG muscle volume, fascicle length or PCSA between the SCP1 and SCP3 groups
D diplegia, H hemiplegia, L left, R right, GMFCS Gross Motor Function Classification System, AFO ankle–foot orthoses, NO no orthosis, HNGD hinged orthosis, SLD solid orthosis, B bilateral, Dose total BoNT-A dose (U) to the involved leg (SCP1 = 1 × 6 U/kg, SCP3 = 3 × 6 U/kg), PCSA physiological cross-sectional area, MAD median absolute deviation, r effect size
aSignificant within-group difference from baseline to 12 months follow-up (p < 0.01)